NGeneBio Co., Ltd. (KOSDAQ:354200)

NGeneBio Statistics

Total Valuation

NGeneBio has a market cap or net worth of KRW 50.58 billion. The enterprise value is 54.82 billion.

Market Cap	50.58B
Enterprise Value	54.82B

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

NGeneBio has 25.04 million shares outstanding. The number of shares has increased by 24.68% in one year.

Current Share Class	25.04M
Shares Outstanding	25.04M
Shares Change (YoY)	+24.68%
Shares Change (QoQ)	-29.10%
Owned by Insiders (%)	7.84%
Owned by Institutions (%)	1.05%
Float	17.19M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.38
PB Ratio	3.44
P/TBV Ratio	7.70
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.49
EV / Sales	8.00
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.30

Financial Position

The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.60.

Current Ratio	0.74
Quick Ratio	0.49
Debt / Equity	0.60
Debt / EBITDA	n/a
Debt / FCF	-0.69
Interest Coverage	-10.19

Financial Efficiency

Return on equity (ROE) is -99.16% and return on invested capital (ROIC) is -40.43%.

Return on Equity (ROE)	-99.16%
Return on Assets (ROA)	-28.47%
Return on Invested Capital (ROIC)	-40.43%
Return on Capital Employed (ROCE)	-92.51%
Revenue Per Employee	118.16M
Profits Per Employee	-210.37M
Employee Count	58
Asset Turnover	0.20
Inventory Turnover	2.09

Taxes

Income Tax	-328.88M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.62% in the last 52 weeks. The beta is 1.21, so NGeneBio's price volatility has been higher than the market average.

Beta (5Y)	1.21
52-Week Price Change	-29.62%
50-Day Moving Average	2,005.42
200-Day Moving Average	2,135.85
Relative Strength Index (RSI)	51.80
Average Volume (20 Days)	164,063

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NGeneBio had revenue of KRW 6.85 billion and -12.20 billion in losses. Loss per share was -958.68.

Revenue	6.85B
Gross Profit	2.72B
Operating Income	-15.90B
Pretax Income	-14.10B
Net Income	-12.20B
EBITDA	-12.49B
EBIT	-15.90B
Loss Per Share	-958.68

Balance Sheet

The company has 5.01 billion in cash and 8.81 billion in debt, giving a net cash position of -3.80 billion or -151.90 per share.

Cash & Cash Equivalents	5.01B
Total Debt	8.81B
Net Cash	-3.80B
Net Cash Per Share	-151.90
Equity (Book Value)	14.72B
Book Value Per Share	720.44
Working Capital	-3.11B

Cash Flow

In the last 12 months, operating cash flow was -12.62 billion and capital expenditures -132.38 million, giving a free cash flow of -12.75 billion.

Operating Cash Flow	-12.62B
Capital Expenditures	-132.38M
Free Cash Flow	-12.75B
FCF Per Share	-509.32

Margins

Gross margin is 39.76%, with operating and profit margins of -232.07% and -178.04%.

Gross Margin	39.76%
Operating Margin	-232.07%
Pretax Margin	-205.76%
Profit Margin	-178.04%
EBITDA Margin	-182.19%
EBIT Margin	-232.07%
FCF Margin	n/a

Dividends & Yields

NGeneBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.68%
Shareholder Yield	n/a
Earnings Yield	-24.12%
FCF Yield	-25.21%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NGeneBio has an Altman Z-Score of -3.32 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.32
Piotroski F-Score	2